Gene2Cure Foundation Partners with Viralgen to Advance Gene Therapy Programs
In a groundbreaking collaboration, Gene2Cure Foundation, a nonprofit organization committed to developing gene therapies, has partnered with Viralgen, a leader in adeno-associated virus (AAV) manufacturing. Announced on November 17, 2026, this partnership aims to expedite the clinical translation of innovative gene therapy programs for rare and ultra-rare genetic conditions, particularly benefiting children with limited treatment options.
Key Aspects of the Collaboration
The new partnership will leverage Viralgen's proprietary
Aava™ manufacturing platform to streamline the development of Gene2Cure's investigational therapies. This agreement is crucial for managing the complexities involved in manufacturing gene therapies, which can be challenging due to the unique requirements of each gene therapy program. Initially, the collaboration will focus on specific genetic disorders such as
PUS3 syndrome,
Smith-Lemli-Opitz syndrome, and
GAND, all of which represent critical unmet medical needs.
Viralgen will provide tailored AAV manufacturing services, which include producing materials required for toxicology studies and clinical use. This adaptability in production is essential for progressing through different stages of treatment development. The Aava™ platform is designed to facilitate scalable manufacturing pathways across various AAV serotypes, enabling Gene2Cure to transition their therapies from the
preclinical phase into clinical trials and eventually to commercialization.
Statement from Partners
Prof. Leszek Lisowski, co-founder and President of Gene2Cure Foundation, expressed excitement about the collaboration, stating, "We are thrilled to partner with Viralgen to bring potentially life-saving experimental gene therapies closer to children afflicted with incurable genetic conditions. Our alliance will enable us to develop these therapies more quickly and cost-effectively, which is vital for affected children and their families."
Jimmy Vanhove, CEO of Viralgen, echoed these sentiments, emphasizing that collaboration is critical for advancing gene therapies for rare diseases. He stated, "We are excited to work with Gene2Cure, supporting the progression of their programs through preclinical and clinical development phases by granting them access to our Aava™ manufacturing platform."
About the Organizations
Gene2Cure Foundation
Founded in the United States, the
Gene2Cure Foundation is a 501(c)(3) nonprofit specialized in advancing potentially life-saving gene therapies for children facing rare and ultra-rare genetic disorders. With a commitment to swift and efficient therapy development, Gene2Cure operates internationally, combining scientific, clinical, and manufacturing resources to transform promising research into viable treatments. Their objective is to deliver safe and effective therapies to children as rapidly and affordably as possible, using contributions from philanthropic donations for maximum therapeutic impact.
For further information, visit
gene2cure.com and follow Gene2Cure on social media platforms like LinkedIn, Instagram, Facebook, and YouTube.
Viralgen
Viralgen is a contract development and manufacturing organization (CDMO) that specializes in AAV-based gene therapies. Established in 2017 as a subsidiary of
AskBio Inc. within the
Bayer AG group, Viralgen provides comprehensive support for clients, ranging from early-stage development to large-scale commercial manufacturing. Their proprietary
Pro10™ suspension cell line and the Aava™ platform facilitate high-yield, scalable manufacturing across various AAV serotypes.
Located in
San Sebastián, Spain, Viralgen's state-of-the-art facility is equipped with multiple cGMP suites and has successfully produced over 2,000 AAV batches. More details on their services and innovations can be found at
viralgen.com, and they are active on LinkedIn for updates.
Conclusion
The collaboration between Gene2Cure Foundation and Viralgen marks a significant step forward in the development of gene therapies for rare diseases. With a shared mission to improve the lives of affected children, both organizations are poised to make considerable contributions to the field of gene therapy, providing hope to families and patients dealing with rare genetic conditions.